ComplianceOnline

Weight Loss Pill from Orexigen under FDA Scrutiny

  • Date: December 08, 2010
  • Source: Admin
Webinar All Access Pass Subscription Abstract:

For decades now, doctors and health care providers have been eagerly awaiting safe and efficient weight-loss therapies. Numerous drugs have been launched so far and rejected by the FDA as they failed to meet the agency's criteria. Qnexa from Vivus Inc., and lorcaserin from Arena Pharmaceuticals Inc., are among the list of drugs that failed to gain FDA approval in recent times. Drug trials linked these drugs to potential heart problems, birth defects and cancerous tumors. Earlier this year, Meridia weight loss pill from the Abbott Laboratories stable was also recalled from the market after regulators said it increased the risk of heart attack and stroke.

Bookmark and Share

Trending Compliance Trainings

Trial Master File and Clinical Data Management Regulated by FDA
By - Carolyn Troiano
On Demand Access Anytime
Good Documentation Practice and Record Keeping Regulations (FDA & EMA)
By - Dr. Afsaneh Motamed Khorasani
On Demand Access Anytime
GAMP Data Integrity 21 CFR Part 11 Training Course
By - Kelly Thomas
On Demand Access Anytime
NEW Reclamation Process - Fed Gov't Payments
By - Donna K Olheiser
Live February 11, 2026
Understanding and Preparing for FDA Pharmaceutical Inspections
By - Michael Ferrante
On Demand Access Anytime
How to conduct an effective BSA Audit
By - Justin Muscolino
On Demand Access Anytime
Installation and Qualification of the Packaging Lines
By - John E Lincoln
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading